SCHEMBL8342113

SCHEMBL8342113

Cc1ccc2c(c1)NNN2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.39
CYP2A6 P11509 2/20 0.39
CSNK1G1 Q9HCP0 1/20 0.37
ALDH1A1 P00352 3/20 0.36
MAPT P10636 2/20 0.36
HSD17B10 Q99714 2/20 0.36
GAA P10253 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
ROS1 P08922 1/20 0.35
CDK5 Q00535 1/20 0.35
ACVR1 Q04771 1/20 0.35
LRRK2 Q5S007 1/20 0.35
EPHX2 P34913 1/20 0.35
HTT P42858 1/20 0.35
TDP1 Q9NUW8 4/20 0.35
ACHE P22303 2/20 0.35
TP53 P04637 2/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17950746 0.73 CSNK1G1 (0.46) CYP1A2CSNK1G1ALDH1A1MAPTHSD17B10
SCHEMBL17950676 0.73 ROS1 (0.53) CYP1A2CSNK1G1ALDH1A1MAPTHSD17B10
SCHEMBL7931108 0.72 CSNK1G1 (0.59) CYP1A2CYP2A6CSNK1G1ALDH1A1MAPT
SCHEMBL7934625 0.72 CSNK1G1 (0.59) CYP1A2CYP2A6CSNK1G1ALDH1A1MAPT
SCHEMBL11687569 0.72
SCHEMBL31351353 0.72 CSNK1G1 (0.59) CYP1A2CYP2A6CSNK1G1ALDH1A1MAPT
SCHEMBL24312507 0.69 HTR5A (0.39) CYP1A2CYP2A6ALDH1A1MAPTHSD17B10
SCHEMBL12933671 0.69 ALDH1A1 (0.41) CYP1A2ALDH1A1MAPTHSD17B10GAA
SCHEMBL12264180 0.68 CSNK1G1 (0.50) CYP1A2CYP2A6CSNK1G1ALDH1A1MAPT
SCHEMBL22431926 0.68 CHEK1 (0.41) CYP2A6ALDH1A1SMN1; SMN2TDP1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339882-A1 SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF BETTA PHARMACEUTICALS CO., LTD. (CN) 2023-10-26 US disclosed
EP-4257196-A1 DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS The University of Hong Kong (HK) 2023-10-11 EP disclosed
US-20220213084-A1 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS FUNDACIÓN KERTOR (ES) 2022-07-07 US disclosed
WO-2021057696-A1 HETEROARYL COMPOUND AND APPLICATION THEREOF 隆泰申医药科技(南京)有限公司 2021-04-01 WO disclosed
WO-2020210377-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF NUVATION BIO INC. (US) 2020-10-15 WO disclosed
EP-3216787-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals Incorporated (US) 2017-09-13 EP disclosed
EP-2769722-A1 Compounds for use in inhibiting HIV capsid assembly Ruprecht-Karls-Universität Heidelberg (DE) 2014-08-27 EP disclosed
WO-2004083174-A2 SULFONYL-AMIDINO CONTAINING AND TETRAHYDROPYRIMIDINO CONTAINING COMPOUNDS AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213084-A1 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS HDAC6, HDAC1, HDAC3 CYP1A2 3432/4885CYP2A6 4144/4885CSNK1G1 279/4885
US-20230339882-A1 SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF PTPRF, PTPRCAP, PTPRJ CYP1A2 4533/4885CYP2A6 3925/4885CSNK1G1 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.